Back to Quality Research
ZTSZoetis Inc
Health Care · Pharmaceuticals · Large
$81.03−1.18%
As of 23 Oct 2026Mkt cap $31.5B
Stage 13
AVOID
Fundamentals
57.7/75
Technical
5.0/15
Independent
62.7/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- +15.3%
- 3M
- +5.3%
- 6M
- −30.7%
- 1Y
- −44.9%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 13.3xHist median 26.3x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 15.2x
- FCF yield
- 6.6%
Quality
- ROIC
- 30.2%
- Operating margin
- 38.2%
- FCF margin
- 24.1%
- Current ratio
- 3.1x
Growth
- Revenue growth
- +2.3%Latest FY YoY
- Revenue CAGR
- +5.0%
- EPS CAGR
- +9.0%
- FCF CAGR
- +7.1%
Capital
- Share-count trend
- −2.0%3Y annualised
- Net debt
- $6.7B2.3x OCF
Annual trend
- CAGR 2021–2025
- +5.0%
- Latest · 2025
- $9B
- YoY
- +2.3%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- UNRESEARCHED · NEW RESEARCH
Key takeaway
Awaiting four-lens research.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
- New current Route A/Route B candidate has no completed four-lens research.
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded